Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 28;8(3):55-57.
doi: 10.14338/IJPT-21-00012.1. eCollection 2022 Winter.

Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma

Raymond B Mailhot Vega  1 , Sharon M Castellino  2 , Qinglin Pei  3 , Susan Parsons  4 , Kenneth B Roberts  5 , David Hodgson  6 , Anne-Marie Charpentier  7 , Thomas J Fitzgerald  8   9 , Sandy K Kessel  8 , Frank G Keller  10 , Kara Kelly  11 , Bradford S Hoppe  12
Affiliations
Editorial

Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma

Raymond B Mailhot Vega et al. Int J Part Ther. .
No abstract available

Keywords: Hodgkin lymphoma; health disparities; particle therapy; proton therapy; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Bradford S. Hoppe is an Associate Editor of the International Journal of Particle Therapy. Raymond B. Mailhot Vega reports educational travel grants from Varian and IBA outside the submitted work. The authors have no additional conflicts of interest to disclose.

References

    1. Bitterman DS, Bona K, Laurie F, Kao PC, Terezakis SA, London WB, Haas-Kogan DA. Race disparities in proton radiotherapy use for cancer treatment in patients enrolled in Children's Oncology Group Trials. JAMA Oncol . 2020;6:1465–8. - PMC - PubMed
    1. Mailhot Vega RB, Hoppe BS. A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma. Expert Rev Hematol . 2020;13:197–200. - PubMed
    1. Tseng YD, Cutter DJ, Plastaras JP, Parikh RR, Cahlon O, Chuong MD, Dedeckova K, Khan MK, Lin SY, McGee LA, Shen EY, Terezakis SA, Badiyan SN, Kirova YM, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, Hoppe BS. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys . 2017;99:825–42. - PubMed
    1. National Cancer Institute (NCI) Brentuximab vedotin and combination chemotherapy in treating children and young adults with stage IIB or stage IIIB-IVB Hodgkin lymphoma. 2021. https://clinicaltrials.gov/ct2/show/NCT02166463 ClinicalTrials.gov Identifier: NCT02166463. Accessed March 1.
    1. Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, Bhatia S, Henderson TO, Schwartz CL, Castellino SM. Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: a Children's Oncology Group Study. J Clin Oncol . 2019;37:3009–17. - PMC - PubMed

Publication types

LinkOut - more resources